A validated high performance liquid chromatography – diode array detector method for the quantification of mitomycin C in plasma, peritoneal fluid and urine
- 27 August 2018
- journal article
- research article
- Published by Taylor & Francis in Journal of Liquid Chromatography & Related Technologies
- Vol. 41 (13-14) , 839-848
Abstract
Mitomycin C (MMC) is a quinone-containing alkylating agent, that has been extensively studied in preclinical and clinical work due to its antitumor activity. A thoroughly validated high performance liquid chromatography-diode array detector method is provided to quantify MMC in plasma, peritoneal fluid and urine. Porfiromycin served as internal standard. The mobile phase for the plasma, peritoneal fluid and urine analysis consisted of 27% MeOH and 73% 20 mM ammoniumacetate buffer (pH 6.5) and 9% ACN and 91% 20 mM phosphate buffer (pH 6.5) respectively. The residue from 100 µL ACN deproteinated plasma was dissolved in 250 µL mobile phase. Peritoneal fluid and urine were diluted 10-fold in their respective mobile phases. UV detection was performed at 365 nm. Quantification of MMC was achieved over a linear range of 0.05–5 µg/mL and 5–50 µg/mL in plasma; 0.1–5 µg/mL and 5–100 µg/mL in peritoneal fluid; 0.25–5 µg/mL and 5–100 µg/mL in urine. The limit of quantification was 0.05 µg/mL in plasma, 0.1 µg/mL in peritoneal fluid and 0.25 µg/mL in urine. The method was further validated for selectivity, specificity, inter- and intraday precision and accuracy (≤15%), extraction recovery and stability. MMC remains stable in the different biofluids for 20 days (short-term stability) at 4 °C, −27 °C and −80 °C and for 80 days (long-term stability) at −80 °C. Graphical AbstractKeywords
Funding Information
- Agency for Innovation by Science and Technology (141631)
- Limburg Sterk Merk (LSM), Hasselt University, Ziekenhuis Oost-Limburg and Jessa Hospital
This publication has 20 references indexed in Scilit:
- Hyperthermic Intraperitoneal ChemotherapySurgical Oncology Clinics of North America, 2012
- Changes induced by surgical and clinical factors in the pharmacology of intraperitoneal mitomycin C in 145 patients with peritoneal carcinomatosisCancer Chemotherapy and Pharmacology, 2010
- 8-Year Follow-up of Randomized Trial: Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy in Patients with Peritoneal Carcinomatosis of Colorectal CancerAnnals of Surgical Oncology, 2008
- Investigations on safety of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with Mitomycin CEuropean Journal of Surgical Oncology, 2006
- Pharmacokinetic changes induced by the volume of chemotherapy solution in patients treated with hyperthermic intraperitoneal mitomycin CCancer Chemotherapy and Pharmacology, 2005
- Pharmacokinetics of Mitomycin C (MMC) after Intraperitoneal Administration of MMC-Gelatin Gel and Its Anti-tumor Effects against Sarcoma-180 Bearing MiceJournal of Drug Targeting, 1997
- Direct injection isocratic high-performance liquid chromatographic analysis of mitomycin C in plasmaJournal of Chromatography B: Biomedical Sciences and Applications, 1996
- High-performance liquid chromatographic determination of mitomycin C in rat and human plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1989
- Liquid chromatographic determination of mitomycin C in human plasma and urineJournal of Chromatography B: Biomedical Sciences and Applications, 1983
- High-performance liquid chromatographic determination of the antitumor agent mitomycin c in human blood plasmaAnalytica Chimica Acta, 1981